Welcome to our dedicated page for HIKMA PHARMS PLC S/ADR news (Ticker: HKMPY), a resource for investors and traders seeking the latest updates and insights on HIKMA PHARMS PLC S/ADR stock.
Hikma Pharmaceuticals PLC (Hikma) is a multinational pharmaceutical company headquartered in the UK, with a global presence across North America, the Middle East and North Africa (MENA), and Europe. With over 45 years of experience, Hikma focuses on creating high-quality medicines and making them accessible to millions of people. The company transforms cutting-edge science into innovative solutions that improve people's lives. Hikma is committed to providing a broad range of branded and non-branded generic medicines, shaping a healthier world for all communities. Through collaborations, partnerships, and ventures, Hikma is at the forefront of advancing precision medicine and healthcare technologies globally.
Hikma Pharmaceuticals participated in a naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day. The event, held at Groves High School in Savannah, Georgia, marks Hikma's milestone of donating over 600,000 doses of naloxone in the past three years. Hikma is working with government officials and the White House Office of National Drug Control Policy to expand access to naloxone, a vital tool for reversing overdoses.
Hikma manufactures multiple forms of naloxone, including generic injectable vials, prefilled syringes, and KLOXXADO® (naloxone 8mg) intranasal spray. The company's Hikma Community Health initiative partners with frontline organizations to expand naloxone access through donations, partnerships, and awareness programs. Hikma also provides a Co-Pay Assistance Program for KLOXXADO® to increase accessibility and reduce out-of-pocket costs.
Hikma Pharmaceuticals PLC announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. This change applies to products manufactured from March 2024 onwards. KLOXXADO® contains twice the naloxone dose of Narcan® Nasal Spray 4mg, offering a important treatment option for opioid overdose reversal.
The extended shelf-life is particularly beneficial for frontline responders and individuals carrying KLOXXADO® for emergency use. This development comes as organizations like the CDC and American Medical Association note that higher doses of naloxone may be necessary to counteract poisoning from illicit fentanyl and other synthetic opioids. Hikma emphasizes its role in combating the opioid crisis, especially as International Overdose Awareness Day approaches on August 31st.
Hikma Pharmaceuticals and Glenmark Specialty announced the US launch of RYALTRIS™, a nasal spray for treating seasonal allergic rhinitis (SAR), approved by the FDA for patients aged 12 and older. This combination therapy relieves nasal and ocular symptoms, offering onset relief in 15 minutes. With 60 million Americans affected by allergic rhinitis, this product addresses a significant unmet need, particularly as many patients report inadequate symptom control. Hikma aims to expand its specialty business in the US through this launch, utilizing its existing salesforce to reach healthcare providers.
Hikma Pharmaceuticals PLC has publicly clarified that it has not engaged in any transaction with Opiant Pharmaceuticals, directly contradicting a prior announcement from PR Newswire. The earlier communication suggested Hikma entered into a commercialization and licensing agreement for OPNT003, Nasal Nalmefene, in Europe and the UK, which Hikma has confirmed is not the case. This statement helps to prevent any potential misinterpretations regarding Hikma's current partnerships and licensing activities.
FAQ
What is the current stock price of HIKMA PHARMS PLC S/ADR (HKMPY)?
What is the market cap of HIKMA PHARMS PLC S/ADR (HKMPY)?
Where is Hikma Pharmaceuticals PLC headquartered?
What is the focus of Hikma Pharmaceuticals PLC?
How long has Hikma Pharmaceuticals PLC been in operation?
In which regions does Hikma Pharmaceuticals PLC operate?